Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Authors' conclusion
Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo.
Study context
- Population
- Adults with obesity (BMI ≥30) and clinical and radiologic moderate knee OA with at least moderate pain81.6% women
- Participants
- 407 adults
- Comparison
- Once-weekly subcutaneous semaglutide 2.4 mg vs placebo, both with counselling on physical activity and a reduced-calorie diet
- Primary endpoint
- Co-primary: percentage change in body weight and change in WOMAC pain score (0-100, higher worse) from baseline
- Follow-up
- Week 68
Methodological detailsdouble-blind, placebo-controlled, 61 sites in 11 countries, 2:1 randomisation
- Double-blind
- Placebo-controlled
- 61 sites in 11 countries
- 2:1 randomisation
Primary result
As reported in the abstract
Body weight, mean % change
Semaglutide
−13.7
mean · %
Placebo
−3.2
mean · %
P < 0.001
Secondary outcomes
Mean, points
| Outcome | Semaglutide | Placebo | P value |
|---|---|---|---|
| Co-primary: WOMAC pain score (0-100), mean change · week 68 | −41.7 | −27.5 | P < 0.001 |
| SF-36 physical-function score (0-100, higher better), mean change (key confirmatory secondary end point) | 12.0 | 6.5 | P < 0.001 |
Safety
Adverse events leading to permanent discontinuation of the trial regimen
- Adverse events leading to permanent discontinuation of the trial regimen: gastrointestinal disorders the most common reason for discontinuation
Serious adverse events
- Incidence similar in the two groups
Original publication
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. N Engl J Med. Published 31 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →